The FDA clinical hold covers two Phase 3 studies for nexiguran ziclumeran, or nex-z, an experimental gene-editing therapy for transthyretin amyloidosis. Nex-z uses the CRISPR gene-editing technology to inactivate the gene that codes for the protein driving this rare disease.
The post Liver Complications Lead FDA to Stop Tests of Intellia Gene-Editing Therapy for a Rare Disease appeared first on MedCity News.
Hackers Exploiting Windows Server Update Services Flaw to Steal Sensitive Data from Organizations
Windows Server Update Services (WSUS) vulnerability is actively exploited in the wild. Criminals are using this vulnerability to steal sensitive data from organizations in various
